Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Intellia Therapeutics stock | $134.21

Learn how to easily invest in Intellia Therapeutics stock.

Intellia Therapeutics Inc is a biotechnology business based in the US. Intellia Therapeutics shares (NTLA) are listed on the NASDAQ and all prices are listed in US Dollars. Intellia Therapeutics employs 312 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Intellia Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NTLA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Intellia Therapeutics stock price (NASDAQ: NTLA)

Use our graph to track the performance of NTLA stocks over time.

Intellia Therapeutics shares at a glance

Information last updated 2021-10-17.
Latest market close$134.21
52-week range$22.17 - $202.73
50-day moving average $146.16
200-day moving average $115.78
Wall St. target price$175.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.90

Buy Intellia Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Intellia Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Intellia Therapeutics price performance over time

Historical closes compared with the close of $134.21 from 2021-10-21

1 week (2021-10-15) 2.85%
1 month (2021-09-23) -13.56%
3 months (2021-07-23) -2.54%
6 months (2021-04-23) 71.43%
1 year (2020-10-22) 440.95%
2 years (2019-10-22) 1,098.30%
3 years (2018-10-22) 511.71%
5 years (2016-10-21) 873.95%

Intellia Therapeutics financials

Revenue TTM $41.8 million
Gross profit TTM $-92,414,000
Return on assets TTM -19.98%
Return on equity TTM -43.73%
Profit margin 0%
Book value $7.24
Market capitalisation $9.6 billion

TTM: trailing 12 months

Shorting Intellia Therapeutics shares

There are currently 3.5 million Intellia Therapeutics shares held short by investors – that's known as Intellia Therapeutics's "short interest". This figure is 0.8% down from 3.5 million last month.

There are a few different ways that this level of interest in shorting Intellia Therapeutics shares can be evaluated.

Intellia Therapeutics's "short interest ratio" (SIR)

Intellia Therapeutics's "short interest ratio" (SIR) is the quantity of Intellia Therapeutics shares currently shorted divided by the average quantity of Intellia Therapeutics shares traded daily (recently around 833820.81339713). Intellia Therapeutics's SIR currently stands at 4.18. In other words for every 100,000 Intellia Therapeutics shares traded daily on the market, roughly 4180 shares are currently held short.

However Intellia Therapeutics's short interest can also be evaluated against the total number of Intellia Therapeutics shares, or, against the total number of tradable Intellia Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Intellia Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Intellia Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0526% of the tradable shares (for every 100,000 tradable Intellia Therapeutics shares, roughly 53 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Intellia Therapeutics.

Find out more about how you can short Intellia Therapeutics stock.

Intellia Therapeutics share dividends

We're not expecting Intellia Therapeutics to pay a dividend over the next 12 months.

Intellia Therapeutics share price volatility

Over the last 12 months, Intellia Therapeutics's shares have ranged in value from as little as $22.17 up to $202.73. A popular way to gauge a stock's volatility is its "beta".

NTLA.US volatility(beta: 2.17)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intellia Therapeutics's is 2.1704. This would suggest that Intellia Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Intellia Therapeutics overview

Intellia Therapeutics, Inc. , a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc.

Frequently asked questions

What percentage of Intellia Therapeutics is owned by insiders or institutions?
Currently 9.921% of Intellia Therapeutics shares are held by insiders and 82.608% by institutions.
How many people work for Intellia Therapeutics?
Latest data suggests 312 work at Intellia Therapeutics.
When does the fiscal year end for Intellia Therapeutics?
Intellia Therapeutics's fiscal year ends in December.
Where is Intellia Therapeutics based?
Intellia Therapeutics's address is: 40 Erie Street, Cambridge, MA, United States, 02139
What is Intellia Therapeutics's ISIN number?
Intellia Therapeutics's international securities identification number is: US45826J1051
What is Intellia Therapeutics's CUSIP number?
Intellia Therapeutics's Committee on Uniform Securities Identification Procedures number is: 45826J105

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site